The agreement enables DIAB to utilise the 3A PET patent family relevant to DIAB's Divinycell P manufacturing with unlimited restrictions for an indefinite time period.
“We are pleased to get access to excellent PET technology that gives us continued ability to provide Divinycell P," says DIAB CEO Anders Paulsson. "For our customers this means no change, they can continue to buy our Divinycell P products to our certified data sheets.”
